Payment overview · 2025
General Payments
$421.41
30 reported records · 5 companies
Healthcare provider profile · identity verified
Lauren Hadney, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PARMA, OH · NPI 1124525449
Verified facts
What the public records show
CMS Open Payments records show Lauren Hadney, DO received $421.41 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 64.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $272.89 | 64.8% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.43 | 18.1% | 5 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $34.15 | 8.1% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $19.27 | 4.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.67 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $421.41 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $208.78 | 14 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $207.08 | 15 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $34.15 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $30.91 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $13.22 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 45 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 103 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 112 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
112 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
45 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
72 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
103 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 560 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 417 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 392 | 109 |
| Losartan Potassium | Losartan Potassium | 380 | 115 |
| Lisinopril | Lisinopril | 318 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 74 |
| Omeprazole | Omeprazole | 214 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 63 |
| Metformin Hcl Er | Metformin Hcl | 205 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 204 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 61 |
| Trazodone Hcl | Trazodone Hcl | 192 | 52 |
| Gabapentin | Gabapentin | 175 | 47 |
| Simvastatin | Simvastatin | 159 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 56 |
| Alendronate Sodium | Alendronate Sodium | 148 | 42 |
| Metformin Hcl | Metformin Hcl | 129 | 38 |
| Sertraline Hcl | Sertraline Hcl | 126 | 29 |
| Atenolol | Atenolol | 112 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 32 |
| Synthroid | Levothyroxine Sodium | 112 | 26 |
| Furosemide | Furosemide | 109 | 38 |
| Ozempic | Semaglutide | 103 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 95 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 89 | 25 |
| Allopurinol | Allopurinol | 87 | 27 |
| Bupropion Xl | Bupropion Hcl | 85 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 22 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 72 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 24 |
| Potassium Chloride | Potassium Chloride | 70 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 67 | 55 |
| Mounjaro | Tirzepatide | 67 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 21 |
| Glimepiride | Glimepiride | 66 | 22 |
| Montelukast Sodium | Montelukast Sodium | 65 | 18 |
| Carvedilol | Carvedilol | 60 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 59 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 14 |
| Spironolactone | Spironolactone | 58 | 20 |
| Sumatriptan Succinate | Sumatriptan Succinate | 58 | 11 |
| Meloxicam | Meloxicam | 57 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 16 |
| Xarelto | Rivaroxaban | 53 | 16 |
| Alprazolam | Alprazolam | 52 | 17 |
| Ezetimibe | Ezetimibe | 50 | 17 |
| Celecoxib | Celecoxib | 49 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 48 | 34 |
| Eliquis | Apixaban | 45 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 11 |
| Jardiance | Empagliflozin | 41 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Meclizine Hcl | Meclizine Hcl | 39 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 36 | 13 |
| Januvia | Sitagliptin Phosphate | 36 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 31 |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Valsartan | Valsartan | 34 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 33 | 21 |
| Estradiol | Estradiol | 33 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Lorazepam | Lorazepam | 31 | 11 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 29 | suppressed |
| Telmisartan | Telmisartan | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | 11 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Famotidine | Famotidine | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 27 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Fluconazole | Fluconazole | 26 | 19 |
| Torsemide | Torsemide | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 23 | suppressed |
| Nyamyc | Nystatin | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Nystatin | Nystatin | 19 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | suppressed |
| Azithromycin | Azithromycin | 18 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Folic Acid | Folic Acid | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 15 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $421.41 · 30 records | ABBVIE INC. | AREXVY, ELIQUIS, Ozempic, QULIPTA, SHINGRIX, SYNTHROID, UBRELVY, VRAYLAR, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error